Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Hang Quach, Bradley Augustson, Hanlon Sia, Nishi Shah, Eben I Lichtman, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Maria Pihlgren, Beata Holkova, Cyril Konto, Lida Pacaud, Amit Khot

Blood (2024) 144 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2024-208189

Published: 2024

Journal Articles

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Binod Dhakal, Hang Quach, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, Camille Martinet, Dominique Duchesne, Andrew Garton, Vinu Menon, Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2024-209952

Published: 2024

Journal Articles

ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection

Vinu Menon, Lida Pacaud, Beata Holkova, Sunitha Gn, Andrew Garton, Maria Pihlgren, Tomomi Matsuura, Piet H van der Graft, Mario Perro, Cyril Konto

Blood (2024) 144 (Supplement 1): 6854.

https://doi.org/10.1182/blood-2024-209580

Published: 2024

Journal Articles

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Natalie S. Callander, Vincent Ribrag, Paul G. Richardson, Ajay K. Nooka, Kevin Song, Katarina Uttervall, Monique C. Minnema, Katja Weisel, Hang Quach, Chang-Ki Min, Marc S. Ballas, Xiaofang Li, Nirav Ratia, Morrys Kaisermann, Beata Holkova, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 897.

https://doi.org/10.1182/blood-2021-152662

Published: 2021

Journal Articles

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139182

Published: 2020

Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska

Blood (2019) 134 (Supplement_1): 1857.

https://doi.org/10.1182/blood-2019-129879

Published: 2019

Journal Articles

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Blood (2016) 128 (22): 104.

https://doi.org/10.1182/blood.V128.22.104.104

Published: 2016

Journal Articles

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Andres Forero-Torres, Beata Holkova, Jerome Goldschmidt, Robert Chen, Gregg Olsen, Ralph V. Boccia, Rodolfo E. Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Maria Corinna Palanca-Wessels, Yinghui Wang, Christopher A. Yasenchak

Blood (2015) 126 (26): 2798–2804.

https://doi.org/10.1182/blood-2015-06-644336

Published: 2015

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Christopher A. Yasenchak, MD, Ahmad Halwani, MD, Ranjana Advani, Stephen Ansell, MD PhD, Lihua Elizabeth Budde, MD PhD, John M. Burke, MD, Charles M. Farber, MD PhD, Beata Holkova, MD, Luis E. Fayad, MD, Kathryn S. Kolibaba, MD, Mark Knapp, MD, Martha Li, PhD, Thomas J. Manley, MD, Dipti Patel-Donnelly, MD, Mahesh Seetharam, MD, Habte A. Yimer, MD, Nancy L Bartlett, MD

Blood (2015) 126 (23): 814.

https://doi.org/10.1182/blood.V126.23.814.814

Published: 2015

Journal Articles

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari, MD, Saurabh Chhabra, MD, Saad Usmani, MD, Sarah Larson, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Cristina Gasparetto, MD, Beata Holkova, MD, Matthew Lunning, DO, Jason Valent, MD, Larry D. Anderson, Jr., MD PhD, Chatchada Karanes, MD, Long Kwei, PhD, Lipo Chang, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Kevin McDonagh, MD

Blood (2015) 126 (23): 377.

https://doi.org/10.1182/blood.V126.23.377.377

Published: 2015

Journal Articles

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 294.

https://doi.org/10.1182/blood.V124.21.294.294

Published: 2014

Journal Articles

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Shuo Ma, MD PhD, Amy Kimball, MD PhD, Mary Beth Tombes, RN, Ellen Shrader, BS, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Amanda Garnett Singh, RN, BSN, April Dean, BS, Sarah Conine, PhD, Heidi Sankala, PhD, John D. Roberts, MD, Thomas C. Shea, MD, Steven Grant, MD

Blood (2014) 124 (21): 3050.

https://doi.org/10.1182/blood.V124.21.3050.3050

Published: 2014

Journal Articles

Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study

Christopher A. Yasenchak, MD, Charles M. Farber, MD PhD, Lihua Elizabeth Budde, MD, Stephen M. Ansell, MD PhD, Ranjana Advani, MD, Beata Holkova, MD, Ahmad Halwani, MD, Mark Knapp, MD, Luis Fayad, MD, Kathryn S. Kolibaba, MD, Dipti Patel-Donnelly, MD, Mahesh Seetharam, Thomas J. Manley, MD, Nancy L. Bartlett, MD

Blood (2014) 124 (21): 1745.

https://doi.org/10.1182/blood.V124.21.1745.1745

Published: 2014

Journal Articles

Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Paul M. Barr, MD, Mary Beth Tombes, RN, Ellen Shrader, BS, Erin Cebula, MPH, CCRP, Emily Pierce, RN, CCRC, Megan M. Herr, BS, Heidi Sankala, PhD, Changyong Feng, PhD, Richard I Fisher, MD, Steven Grant, MD, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 4375.

https://doi.org/10.1182/blood.V122.21.4375.4375

Published: 2013

Journal Articles

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Christopher A. Yasenchak, MD, Robert Chen, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Beata Holkova, MD, Peter J. Rosen, MD, Jonathan W. Friedberg, MD, Megan M. O'Meara, MD, Andres Forero-Torres, MD

Blood (2013) 122 (21): 4389.

https://doi.org/10.1182/blood.V122.21.4389.4389

Published: 2013

Journal Articles

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

Beata Holkova, MD, Thomas C. Shea, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 1794.

https://doi.org/10.1182/blood.V120.21.1794.1794

Published: 2012

Journal Articles

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Beata Holkova, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Guillermo Garcia-Manero, MD, Steven Grant, MD

Blood (2012) 120 (21): 3588.

https://doi.org/10.1182/blood.V120.21.3588.3588

Published: 2012

Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 2959.

https://doi.org/10.1182/blood.V120.21.2959.2959

Published: 2012

Journal Articles

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Lubomir Sokol, MD, PhD, Kristy L. Richards, PhD, MD, Samir Parekh, MD, Rebecca Elstrom, MD, Ashraf Z. Badros, MD, Igor Espinoza-Delgado, MD, Michael J. Schell, PhD, Amy Kimball, MD, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Domenico Coppola, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, John D. Roberts, MD, Steven Grant, MD

Blood (2011) 118 (21): 779.

https://doi.org/10.1182/blood.V118.21.779.779

Published: 2011

Journal Articles

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Adriana Zingone, MD, PhD, Neha Korde, MD, Jinqiu Chen, PhD, Liqiang Xi, MD, Mark Raffeld, MD, Beata Holkova, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, Austin Doyle, MD, Irina Maric, MD, Katherine Calvo, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Christina Annunziata, MD, PhD, Steven Grant, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 306.

https://doi.org/10.1182/blood.V118.21.306.306

Published: 2011

NARROW

First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study

Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas

A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only